Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-*versus*-host disease

Melinda E. Christensen,[1,2,4] Brie E. Turner,[1,5] Laura J. Sinfield,[1] Katarina Kollar,[3] Hannah Cullup,[1,4] Nigel J. Waterhouse,[2,4] Derek N.J. Hart,[1,6] Kerry Atkinson,[3,4] and Alison M. Rice[1,4]

[1]Bone Marrow Transplant Team, [2]Apoptosis and Cytotoxicity Laboratory, [3]Adult Stem Cell Team, Mater Medical Research Institute, South Brisbane, Queensland, Australia, [4]University of Queensland, Brisbane, Queensland, Australia, [5]Current address: Australian Red Cross Blood Service, Sydney, NSW, Australia, [6]Current address: ANZAC Research Institute, University of Sydney, NSW, Australia

*Citation: Christensen ME, Turner BE, Sinfield LL, Kollar K, Cullup H, Waterhouse NJ, Hart DNJ, Atkinson K, and Rice AM. Mesenchymal stromal cells transiently alter the inflammatory milieu post-transplant to delay graft-*versus*-host disease. Haematologica 2010;95(12):2102-2110. doi:10.3324/haematol.2010.028910*



Online Supplementary Figure S1. Third party MSC suppress T-cell proliferation and inflammatory cytokines *in vitro*. Irradiated UBI-GFP/BL6 MSC were co-cultured in a mixed lymphocyte reaction with irradiated BALB/c (host) stimulators and B10.Br purified T cells (donor). T-cell proliferation, measured by ^{3}H-thymidine incorporation, was significantly reduced in the presence of MSC (A, $P<0.01$, n=6). The inflammatory cytokines TNFα (B) and IFNγ (C) were assessed in supernatants by cytokine bead array after the mixed lymphocyte reaction (n=3 independent experiments, IFNγ: $P<0.01$; TNFα: $P<0.05$). Data presented as mean ± SEM.



Online Supplementary Figure S2. Therapeutic administration of MSC does not affect survival in mice with established GVHD after MHC-matched, miHA-mismatched HSCT. BALB.B mice were transplanted with UBI-GFP/BL6 bone marrow and splenocytes and administered $4x10^5$/mouse via intraperitoneal injection once GVHD was established. Mice were monitored daily for GVHD. N=3 per cohort.